CoChat

Prevalence and Predictors of Abnormal Cardiovascular Responses to Exercise Testing Among Individuals With Type 2 Diabetes

Open access

The DOI matches its Crossref record, with a small difference in title or year; 27 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We examined maximal graded exercise test (GXT) results in 5,783 overweight/obese men and women, aged 45–76 years, with type 2 diabetes, who were entering the Look AHEAD (Action for Health in Diabetes) study, to determine the prevalence and correlates of exercise-induced cardiac abnormalities. RESEARCH DESIGN AND METHODS: Participants underwent symptom-limited maximal GXTs. Questionnaires and physical examinations were used to determine demographic, anthropometric, metabolic, and health status predictors of abnormal GXT results, which were defined as an ST segment depression ≥1.0 mm, ventricular arrhythmia, angina pectoris, poor postexercise heart rate recovery (<22 bpm reduction 2 min after exercise), or maximal exercise capacity less than 5.0 METs. Systolic blood pressure response to exercise was examined as a continuous variable, without a threshold to define abnormality. RESULTS: Exercise-induced abnormalities were present in 1,303 (22.5%) participants, of which 693 (12.0%) consisted of impaired exercise capacity. ST segment depression occurred in 440 (7.6%), abnormal heart rate recovery in 206 (5.0%), angina in 63 (1.1%), and arrhythmia in 41 (0.7%). Of potential predictors, only greater age was associated with increased prevalence of all abnormalities. Other predictors were associated with some, but not all, abnormalities. Systolic blood pressure response decreased with greater age, duration of diabetes, and history of cardiovascular disease. CONCLUSIONS: We found a high rate of abnormal GXT results despite careful screening for cardiovascular disease symptoms. In this cohort of overweight and obese individuals with type 2 diabetes, greater age most consistently predicted abnormal GXT. Long-term follow-up of these participants will show whether these abnormalities are clinically significant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1787

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study entry flow diagram. Participants included in the present analysis were the 5,783 individuals seen in screening visit 3.
Figure 1 Study entry flow diagram. Participants included in the present analysis were the 5,783 individuals seen in screening visit 3.CC BY-NC-ND · PubMed Central
Figure 2 Number or prevalence (%) of abnormal test prevalence by predictor variables. A: Number of abnormal tests. B: Abnormal test prevalence (%) by sex: ■, men; □, women. C: Abnormal test prevalence (%) by age: ■, 45–54 years; ▤, 55–64 years; □, 65–75 years. D: Abnormal test prevalence (%) by ethnicity: ■, Latino; □, not Latino. E: Abnormal test prevalence (%) by race: ■, African American; ▤, American Indian; □, white; ▧, other/multiracial/unknown. F: Abnormal test prevalence (%) by use of blood pressure medicines: ■, yes; □, no. G: Abnormal test prevalence (%) by systolic blood pressure: ■, <120 mmHg; ▤, 120–129 mmHg; □, 130–139 mmHg; ▧, 140–149 mmHg; , 150–159 mmHg. H: Abnormal test prevalence (%) by diastolic blood pressure: ■, <70 mmHg; ▤, 70–84 mmHg; □, at least 85 mmHg. I: Abnormal test prevalence (%) by years with diabetes: ■, <5 years; ▤, 5 to <10 years; □, at least 10 years. J: Abnormal test prevalence (%) by cardiovascular disease history: ■, yes; □, no. K: Abnormal test prevalence (%) by BMI: ■, 25 to <30 kg/m2; ▤, 30 to <35 kg/m2; □, 35 to <40 kg/m2; ▧, at least 40 kg/m2. L: Abnormal test prevalence (%) by use of insulin: ■, yes; □, no. *P < 0.05. Ang, Exercise-induced angina; Arr, ventricular arrhythmia (ventricular fibrillation, ventricular tachycardia, runs of at least three premature ventricular beats, or exercise-induced bundle branch block); Any, any abnormality from among those listed; Ex C, impaired exercise capacity (highest achieved workload of <5.0 METs; HRR, heart rate recovery of <22 bpm over 2 min after exercise; ST, ST segment depression of at least 1.0 mm.
Figure 2 Number or prevalence (%) of abnormal test prevalence by predictor variables. A: Number of abnormal tests. B: Abnormal test prevalence (%) by sex: ■, men; □, women. C: Abnormal test prevalence (%) by age: ■, 45–54 years; ▤, 55–64 years; □, 65–75 years. D: Abnormal test prevalence (%) by ethnicity: ■, Latino; □, not Latino. E: Abnormal test prevalence (%) by race: ■, African American; ▤, American Indian; □, white; ▧, other/multiracial/unknown. F: Abnormal test prevalence (%) by use of blood pressure medicines: ■, yes; □, no. G: Abnormal test prevalence (%) by systolic blood pressure: ■, <120 mmHg; ▤, 120–129 mmHg; □, 130–139 mmHg; ▧, 140–149 mmHg; , 150–159 mmHg. H: Abnormal test prevalence (%) by diastolic blood pressure: ■, <70 mmHg; ▤, 70–84 mmHg; □, at least 85 mmHg. I: Abnormal test prevalence (%) by years with diabetes: ■, <5 years; ▤, 5 to <10 years; □, at least 10 years. J: Abnormal test prevalence (%) by cardiovascular disease history: ■, yes; □, no. K: Abnormal test prevalence (%) by BMI: ■, 25 to <30 kg/m2; ▤, 30 to <35 kg/m2; □, 35 to <40 kg/m2; ▧, at least 40 kg/m2. L: Abnormal test prevalence (%) by use of insulin: ■, yes; □, no. *P < 0.05. Ang, Exercise-induced angina; Arr, ventricular arrhythmia (ventricular fibrillation, ventricular tachycardia, runs of at least three premature ventricular beats, or exercise-induced bundle branch block); Any, any abnormality from among those listed; Ex C, impaired exercise capacity (highest achieved workload of <5.0 METs; HRR, heart rate recovery of <22 bpm over 2 min after exercise; ST, ST segment depression of at least 1.0 mm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Curtis, J. M., Horton, E. S., Bahnson, J., Gregg, E. W., Jakicic, J. M., Regensteiner, J. G., Ribisl, P. M., Soberman, J. E., Stewart, K. J., Espeland, M. A., & for the Look AHEAD Research Group
Affiliations
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
  • Joslin Diabetes Center (US)
  • Wake Forest University Health Sciences (US)
  • Centers for Disease Control and Prevention (US)
  • University of Pittsburgh (US)
  • University of Colorado Anschutz (US)
  • Wake Forest University (US)
  • University of Tennessee, Memphis, Memphis, Tennessee;
  • Johns Hopkins University (US)
Corresponding author
Curtis, Jeffrey M.
Venue
Diabetes Care
Published
2010-01-07
Volume
33
Issue
4
Pages
901-907
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2093701436
Cited by
37
References
28
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3 · 2018: 3 · 2017: 1 · 2016: 2 · 2014: 4 · 2013: 3 · 2012: 2
FWCI
9.41
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health (UL1TR000005)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
Keywords
type 2 diabetes, ST-segment depression, ventricular arrhythmias, angina pectoris, heart rate recovery, exercise capacity, systolic blood pressure response, age as predictor, cardiovascular risk screening, overweight and obesity
MeSH terms
Aged, Cardiovascular Diseases, Cardiovascular System, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Exercise Test, Female, Humans, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.